XM tillhandahåller inte tjänster till personer bosatta i USA.

Dow closes at another record high as chip stocks, retail data support



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>US STOCKS-Dow closes at another record high as chip stocks, retail data support</title></head><body>

Dow ends at record peak for fourth session in five

TSMC gains after forecasting Q4 revenue jump

Travelers, Blackstone at record closes after Q3 profit beats

Elevance Health biggest dip in 4.5 years on profit forecast cut

Indexes: Dow up 0.37%, S&P 500 down 0.02%, Nasdaq up 0.04%

Adds closing prices

By David French

Oct 17 (Reuters) -The Dow Jones Industrial Average advanced onThursday to its fourth record close in the last five sessions, as stronger-than-expected monthly retail sales indicated a robust U.S. consumer and TSMC's upbeat forecast buoyed chipmakers' stocks.

Theother main Wall Street benchmarks were largely unchanged, as theS&P 500 dipped to a fractional loss andthe Nasdaq Composite eked out a tiny win.

Taiwan Semiconductor Manufacturing Co 2330.TW, the world's largest contract chipmaker, beat market estimates for profit and forecast a jump in fourth-quarter revenue, driven by demand for artificial intelligence chips.

The chipmaker's U.S.-listed shares TSM.N soared 9.8%, while artificial intelligence-trade favorite and TSMC customer Nvidia NVDA.O gained 0.9%.

The optimism spread to other chip stocks, sending the broader Philadelphia SE Semiconductor index .SOX 1% higher.

Fresh U.S. data confirmed healthy growth in the world's largest economy, while keeping bets on a 25-basis-point rate cut at the Federal Reserve's next meeting largely intact at 89.4%, according to CME's FedWatch.

U.S. retail sales increased 0.4% in September, slightly more than expected, while weekly jobless claims fell unexpectedly.

A broadly upbeat start to the third-quarter earnings season, strong economic data and the Fed kicking off its policy-easing cycle have pushed the Dow and the S&P 500 to record highs in recent sessions, with the latter close to the psychologically important 6,000 mark.

The S&P 500 .SPX lost 1.00 points, or 0.02%, at 5,841.47 points, while the Nasdaq Composite .IXIC climbed 6.53 points, or 0.04%, to 18,373.61. The Dow Jones Industrial Average .DJI rose 161.35 points, or 0.37%, to 43,239.05.

Josh Jamner, investment strategy analyst at ClearBridge Investments, said investors have been revising economic and earnings growth expectations as robust data eased worries about a recession.

However, investors were trying to figure out which companies and sectors will lead the market higher, and when to rotate into them, after months of megacap stocks driving market rallies.

"Overall, it's allowing the market to advance, but maybe in a somewhat more restrained fashion than what otherwise might be expected," Jamner said.

While theDow advanced for the second straight day, small cap indexes fell. The Russell 2000 .RUT dipped 0.3% andthe S&P Small Cap 600 .SPCY slipped 0.2%, a day after closingat their highest in nearly three years.

A majority of S&P 500 sectors were also weaker, including rate-sensitive indexes such as utilities .SPLRCU and real estate <.SPLRCR>, which slipped 0.9% and 0.7%, respectively.

One other quirk is that U.S. equity benchmarks have advanced in recent days even as U.S. Treasury yields have crept up. On Thursday, the benchmark 10-year note yield US10YT=TWEB rose 7.5 basis points to 4.091%.

In earnings-related moves, Travelers Companies TRV.N and Blackstone Group BX.N advanced 9% and 6.3%, respectively, to record closing highs after both the insurer and the money manager posted third-quarter profit which beat market expectations.

The S&P Banks index .SPXBK edged up 0.1%, advancing for afifth straight session, matching its mid-August run and just one off its six successive wins in April, as a slew of larger regional banks posted third-quarter numbers. M&T Bank MTB.N and Synovus Financial SNV.N rose more than 5%, but Truist Financial TFC.N dropped 3.5% and Huntington Bancshares<HBAN.O> slipped 2.6%.

Outside financials, health insurer Elevance Health ELV.N plummeted 10.6%, its biggest one-day drop since the start of the pandemic in March 2020, afterslashing its full-year profit forecast.

Volume on U.S. exchanges was 11.34 billion shares, compared with the 12.08 billion average for the full session over the last 20 trading days.



Reporting by Lisa Mattackal and Purvi Agarwal in Bengaluru and David French in New York; Editing by Pooja Desai and Richard Chang

</body></html>

Ansvarsfriskrivning: XM Group-enheter tillhandahåller sin tjänst enbart för exekvering och tillgången till vår onlinehandelsplattform, som innebär att en person kan se och/eller använda tillgängligt innehåll på eller via webbplatsen, påverkar eller utökar inte detta, vilket inte heller varit avsikten. Denna tillgång och användning omfattas alltid av i) villkor, ii) riskvarningar och iii) fullständig ansvarsfriskrivning. Detta innehåll tillhandahålls därför uteslutande som allmän information. Var framför allt medveten om att innehållet på vår onlinehandelsplattform varken utgör en uppmaning eller ett erbjudande om att ingå några transaktioner på de finansiella marknaderna. Handel på alla finansiella marknader involverar en betydande risk för ditt kapital.

Allt material som publiceras på denna sida är enbart avsett för utbildnings- eller informationssyften och innehåller inte – och ska inte heller anses innehålla – rådgivning och rekommendationer om finansiella frågor, investeringsskatt eller handel, dokumentation av våra handelskurser eller ett erbjudande om, eller en uppmaning till, en transaktion i finansiella instrument eller oönskade finansiella erbjudanden som är riktade till dig.

Tredjepartsinnehåll, liksom innehåll framtaget av XM såsom synpunkter, nyheter, forskningsrön, analyser, kurser, andra uppgifter eller länkar till tredjepartssajter som återfinns på denna webbplats, tillhandahålls i befintligt skick, som allmän marknadskommentar, och utgör ingen investeringsrådgivning. I den mån som något innehåll tolkas som investeringsforskning måste det noteras och accepteras att innehållet varken har varit avsett som oberoende investeringsforskning eller har utarbetats i enlighet med de rättsliga kraven för att främja ett sådant syfte, och därför är att betrakta som marknadskommunikation enligt tillämpliga lagar och föreskrifter. Se till så att du har läst och förstått vårt meddelande om icke-oberoende investeringsforskning och riskvarning om ovannämnda information, som finns här.

Riskvarning: Ditt kapital riskeras. Hävstångsprodukter passar kanske inte alla. Se vår riskinformation.